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Abstract— The holistic management of hearing loss (HL) 
requires appropriate public health policies for HL prevention, 
early diagnosis, long-term treatment and rehabilitation; 
detection and prevention of cognitive decline; protection from 
noise; and socioeconomic inclusion of HL patients. However, 
currently the evidential basis for forming such policies is limited. 
Holistic HL management policies require the analysis of 
heterogeneous data, including Hearing Aid (HA) usage, noise 
episodes, audiological, physiological, cognitive, clinical and 
medication, personal, behavioural, life style, occupational and 
environmental data.  To utilise these data in forming holistic HL 
management policies, EVOTION, a new European research and 
innovation project, aims to develop an integrated platform 
supporting: (a) the analysis of related datasets to enable the 
identification of causal and other effects amongst them using 
various forms of big data analytics, (b) policy decision making 
focusing on the selection of effective interventions related to the 
holistic management of HL, based on the outcomes of (a) and the 
formulation of related public health policies, and (c) the 
specification and monitoring of such policies in a sustainable 
manner. In this paper, we describe the EVOTION approach. 
Keywords— Public health policy; hearing loss; hearing aids; 
big-data analysis 
I. MOTIVATION 
A. Hearing Loss and its consequences 
Hearing Loss (HL) is the most frequent sensory deficit and 
one of the most prevalent chronic diseases, affecting 
approximately one-third of people over the age of 65 and over 
5% of the world’s population [16]. In 2014, WHO estimated 
that in 2012 more than 360 million people had disabling HL, 
i.e., a 3-fold increase from 120 million in 1995 [16]. HL ranks 
as the fifth leading cause of Years Lived with Disability 
(YLD), a component of the Disability-Adjusted Life Year 
(DALY), used to measure the global burden of disease [1]. 
This ranking is higher than diabetes and conditions causing 
visual impairment [1]. Current trends in the spread of HL are 
expected to continue or increase further due to exposure to 
workplace and social noise. In the UK, for example, the 
percentage of people suffering from HL is expected to exceed 
20% of the overall population by 2031 [2].  
The consequences of HL in the overall health condition of 
the people suffering from it are significant. Several studies 
have shown that HL increases the risk of cognitive 
decline/dementia by 20% [3], mental illness [4], depression [4], 
and even the risk of mortality due to reduced physical and 
mental activity and social isolation [5][6]. The latter factors 
also lead to a poorer quality of life overall both in physical and 
mental terms for HL patients [8]. Furthermore, HL increases 
the risk of accidental injury (e.g. HL is associated with 
incidents of falls [3]). 
The economic consequences of HL are also significant. In 
particular, HL results in reduced productivity, unemployment 
or early retirement, loss of income and work discrimination 
[10]. Studies in health economics also indicate that the 
treatment of HL has a significant cost. According to [8], for 
instance, the annual cost of HL in the European Union is 
€213bn. 
B. Challenges in HL management  
Currently, the pre-eminent management strategy for HL is 
the provision of Hearing Aids (HAs). Modern HAs are 
programmable sound amplification devices that are worn by 
hearing impaired to overcome their hearing deficits. HAs can 
detect and classify types of sound environments (e.g., quiet, 
noisy or windy environments; listening to speech or music) and 
manually or automatically switch between different settings, to 
optimise hearing of the patients who wear them in such 
environments. Despite these capabilities, however, the 
currently available HAs can only partially overcome the 
deficits associated with HL and their users face several 
challenges. More specifically, HA users frequently find it 
difficult to select amongst pre-defined settings of HAs [9]. 
They also find their HAs difficult to accustom and frequently 
ineffective. Consequently, they need to visit their clinician 
several times for HA adjustments and often end up not using 
their HAs. Some of the most commonly reported reasons for 
the non-usage of HAs, include the ineffectiveness of HAs in 
noisy situations, due to poor sound quality and perceived 
benefit. Despite the fact that new generation HAs support a 
wide variety of advanced programming settings, literature 
suggests that older adults do not use these as they are less able 
to decide on complex circumstances and alternatives [10]. 
Therefore, the majority (80%) of adults aged 55 to 74 years 
who would benefit from a HA, do not use them [10], and 
nearly 30% of HA users are dissatisfied with their HAs in 
noisy situations [11].  
The key reason underpinning ineffective HA use is that 
HAs are fitted to suit the audiogram rather than the patient’s 
needs and overall profile. Ideally, HA fitting should take into 
account: (a) a range of personal and real life behavioural, 
physiological and other auditory related data; and (b) an 
analysis of the circumstances which are challenging for 
individual HA users on a continuous basis. It should also be 
appropriately supported by individualised rehabilitation 
treatments such as auditory training [12], as HA users depend 
more on their cognitive resources than normal hearing listeners 
in order to understand speech [13]. Nevertheless, evidence on 
how to link such information with appropriate, individualised 
management strategies is still lacking.  
C. Need and role of public policy 
The effective management of HL depends on and requires 
appropriate public health policies (PHP) [1][2]. Public health 
policy affects the affordability and hence access to HAs and 
ongoing treatment services (e.g., HL check-ups, HA 
adjustments, provision of related rehabilitation services). 
Public health policy can also have a significant effect on:  
• the prevention and early diagnosis of HL; 
• the early treatment of diagnosed HL through the provision 
of Has and other assistive devices; 
• the longer-term treatment of HL through systematic 
checks of the hearing, the provision of other vital related 
rehabilitation services including auditory training and 
hearing therapy; 
• the protection of people with hearing impairments from 
the harmful effects of loud noise; and 
• the early detection, delay or even prevention of cognitive 
decline; the set-up of standards, services and technology 
for promoting and ensuring inclusion of participation of 
HL patients with in various settings (e.g., at work, at 
school/educational establishments, in everyday life).  
On-going reforms of PHP in this area (e.g., changes in the 
free provision of HAs for different types of HL in the UK) and 
the spark of social debate that they have caused demonstrate 
the importance of PHP in this area. Examples of policy fields 
that influence big part of the population and mobilize resources 
encountered in billions of euros yearly are cut off points of 
hearing aid fitting covered by insurance, decision for unilateral 
or bilateral HA fitting or cochlear implantation, noise 
protection measures in working environments, and default 
maximum dB levels of electronic devices. 
The management of HL and its consequences at a public 
health policy making level can benefit from the analysis of 
heterogeneous data, including HA usage, noise episodes 
causing threshold shifts, audiological, physiological, cognitive, 
clinical and medication, personal, behavioural, life style data, 
occupational and environmental data. The analysis of these 
types of data using big data analytic techniques can enable the 
investigation of whether HL relates to other comorbidities and 
contextual factors and patterns of such relations. 
The outcomes of such analysis can also enable the 
stratification of related risks and effects to HL patients, and – 
through correlation with other economic, social and physical 
constraints – help developing a holistic systemic perspective of 
over interventions regarding the management of HL. 
Moreover, it can enable the broader support, social and 
occupational inclusion and the well-being of HL patients, 
exploration of missing, under or over-estimated value of 
specific interventions (e.g. noise protection, visualization of 
public announcements etc.) and analysis of their effectiveness. 
II. THE EVOTION VISION 
The overall aim of EVOTION is to enable the types of 
analysis identified in Sect. I.C and support evidence based 
public health policy formation. 
EVOTION aims to do support this through, the 
development of an integrated platform incorporating a big data 
analytics (BDA) platform, which will enable the collection and 
analysis of heterogeneous data related to hearing loss, 
including hearing aid usage, physiological, cognitive, medical, 
personal, occupational, behavioural, life style, environmental 
and open web data. These data will underpin a decision support 
system to the identification, simulation, selection and 
monitoring of the effectiveness of possible and implemented 
interventions related to the management of hearing loss and the 
overall inclusion and well-being of HL patients in processes 
aimed at the formulation of related public health policies, 
based on the outcomes of the BDA. 
The EVOTION platform will support decisions related to 
the formation of public health policies for HL treatment. These 
policies may cover aspects such as: 
• HL treatment rationalisation, including for example 
policies for: (a) the provision of HAs and HA usage 
monitoring and adjustment to increase the frequency and 
efficacy of HA use and to reduce wastage of underused 
HAs; (b) enhancing post HA provision care (aka follow up 
care), remote care and self-management (e.g., remote 
adjustment of HAs to improve access of HA users to 
audiology care services and reduce the cost of the latter); 
(c) HL rehabilitation services (e.g., cognitive 
rehabilitation/auditory training); and/or (d) treating HL as 
a long-term condition and in an integrated manner based 
on multi-morbidity long term indicators. 
• Investigating potential causal mechanisms of HL 
comorbidities, and identifying profiles and multi-level 
factors whose coexistence multiplies risks of HL 
deterioration and/or comorbidities occurrence, in order to 
judge – based on evidence – whether specific interventions 
have worthwhile effects in fields related to HL.  
• Screening/ early detection of HL, including detection of 
noise induced hearing loss (NIHL) 
• Improving the wider health system from the perspective of 
HL, including for example policies for improving access 
to non-HL related health services for HL patients 
• Enhancing the inclusion of HL patients, including, for 
example, policies for: (a) using assisted listening devices 
(ALDs) in public spaces and public transport to support 
good communication, and (b) addressing communication 
challenges for HL patients in occupational contexts (e.g., 
incentives for use of ALDs and alternative visual signals 
in work spaces)  
• Improving the safety of HL patients, including policies for 
improving hearing whilst driving and walking 
• Improving the overall well-being of HL patients including, 
for example, policies aiming to enable/increase physical 
activity of HL patients. 
• Prevention of noise induced hearing loss, social isolation 
and cognitive decline arising from HL 
III. THE EVOTION PLATFORM 
To achieve its overall aim, EVOTION aims to build a 
platform that will integrate: 
• Existing clinical repositories of HL related data including 
personal, medical and occupational data already available 
at the clinical institutions participating in EVOTION. 
• Enhanced HAs enabling the capture and provision of HA 
usage related data (e.g., rating of HA ease or difficulty of 
use in different listening conditions, frequency and type 
adjustments of HA controls).  
• Wearable sensors supporting the collection real time 
contextual HA user physiological data (e.g., heart rate, 
blood pressure, skin conductance) 
• A mobile application with components supporting the 
acquisition and transmission of: (a) behavioural and life 
style data (e.g., recording of HA user daily activities such 
as participation in conversations, watching TV); (b) 
contextual data (e.g., HA user’s location); (c) cognitive 
data (e.g., verbal reaction time); and (d) subjective data 
provided by HA user and/or their carers regarding 
interventions; and the execution of periodic audiological 
and cognitive tests to collect the related data (audiological 
and cognitive test components) 
• A big data analytics (BDA) platform enabling the analysis 
of data collected by the platform, through the use of data 
mining, statistical, text and social media data analysis 
techniques. 
• A simulation component enabling the specification and 
execution of predictive models regarding the potential 
outcomes of different policy alternatives. 
• A decision support system (DSS) enabling the suggestion 
of decisions to policy making stakeholders as justified by 
the supporting evidence arising from the big data 
analytics, and the execution of simulation models.  
• A public health policy decision marking (PHPDM) models 
specification tool supporting the specification of models 
that can drive the decision-making process (see Sect. IV 
below).   
• A social media analysis tool enabling the publication of 
public health policy issues and prospective policy 
decisions (along with supporting evidence) and the 
acquisition and analysis of social network data regarding 
the views of patients and the wider public over these issues 
and the related policies. 
The main components, overall information flow, big data 
analytics, decision support capabilities policy making platform 
envisaged by EVOTION are shown in Figure 1. 
The data collected by the EVOTION solution will be 
correlated and analysed, using BDA techniques, which will be 
employed in order to detect patterns of: 
 
Figure 1.  EVOTION platform, information flows and decision marking 
 
(a) Contextualised HA usage and its effectiveness for 
different types of HL patients (in reference to the 
environment and the activities carried out by HL patients) 
(b) Contextualised TTS episode occurrences for different 
types of HL patients and effectiveness of existing 
preventive measures (e.g. noise protection) 
(c) Contextualised cognitive capabilities for different types of 
HL patients 
(d) Correlations between different factors and comorbidities 
affecting HL and the overall well-being of HL patients 
suffering from it 
In detecting (a)–(d), our key focus will be to identify factors 
and parameters that define subgroups with different treatment 
outcomes, and the risks arise for such subgroups and the 
outcomes. 
The EVOTION platform will support its users to specify 
the types of analysis that they would like to apply upon the 
data collected by the platform in a declarative form, as well as 
the forms in which the outcomes of this analysis can be 
visualised, the certainty thresholds that these outcomes should 
exceed in order to be deemed usable in the decision-making 
process, and the criteria in which they can inform the selection 
of policy alternatives.  The forms of BDA that will be 
performed by the EVOTION platform and the usage of its 
outcomes will be specified as part of PHPDM models (see 
Sect. IV below). 
The envisaged physical architecture of the EVOTION 
solution is shown in Figure 2. As shown in the figure, 
EVOTION will be deployed on a cloud infrastructure and the 
and accept retrospective and prospective (dynamic) data from 
different components, including existing clinical repositories, 
the mobile application that will be part of the platform, 
enhanced HAs and wearable devices (biosensors) available off-
the-shelf. EVOTION HAs will be communicating with the 
EVOTION application to send real time HA usage and 
environment data to it, and receive adaptation control signals 
from it. This will be through the mobile application or directly 
to the platform (for HA users who do not have mobile phones). 
Wearable biosensors will also be sending data to the 
EVOTION platform, through either the mobile phone or 
directly to the platform.  The EVOTION platform will also be 
capable of connecting and receiving existing and periodically 
updateable data from existing clinical repositories (e.g., 
outcomes of audiograms and other hearing aid fitting tests, 
clinical questionnaires etc.). 
IV. PUBLIC HEALTH POLICY DECISION MAKING MODELS 
The operation of the EVOTION platform will be driven by 
public health policy decision-making models (PHPDM 
models). These models will specify: 
(i) the generic goal(s) underpinning the decision to be made 
(e.g. policies regarding the frequency of follow up care for 
patients who have been issued HAs) and the alternative 
decisions that may be made for this goal (e.g., having no, 
one or two follow ups within a specific time period) 
(ii) the criteria to be used for making such decisions (e.g., 
whether the difficulties faced by different types of HA 
users depend on the type of their HL, their cognitive 
capabilities, their life style and behaviour, other 
comorbidities that they may have and/or their overall 
compliance with HA usage guidelines given to them by 
clinicians and whether such difficulties are alleviated 
depending on the number of follow up treatments and the 
time that elapses between them) 
(iii) the BDA evidence required for applying the criteria (e.g., 
whether any combination of the factors considered above 
is a good predictor of the difficulties faced by HA users as 
confirmed by specific types of statistical analysis or data 
mining based classification) and the BDA process for 
producing it 
(iv) simulations that should be executed for exploring the 
consequences of alternative decisions 
(v) processes to be followed for making specific types of 
health policies (e.g., what is the threshold of evidence that 
should be considered sufficient for a particular decision, 
who are the stakeholders whose views should be 
considered and recorded prior to reaching a decision, who 
has responsibility for making the final decision, whether a 
decision should be continually or periodically reviewed 
upon the acquisition of new evidence etc.) 
These models will also provide a structure for organising 
possible alternative decisions in policy making, the arguments 
and rationale for making decisions, the stakeholders 
participating in the decision-making process, the views they 
express and the final decision making rules. Hence, PHPDM 
models will drive a collaborative stakeholder decision making 
process, and provide a structure for recording information that 
will make it traceable and accountable. Furthermore, PHPDM 
models will be specified parametrically to make their 
customisation easy in case that this would be required in 
different policy making settings. Thus, PHPDM models can be 
repeatedly executed in the same or different policy making 
settings (e.g., for making policy on the very same issues in 
different regions).  
The EVOTION platform will provide a tool supporting the 
specification of PHPDM models into some high-level 
language. Their verification and transformation into executable 
BDA and simulation tasks and decision making processes 
would be passed as inputs to the BDA platform, simulator and 
decision support system of the platform to execute them and 
realize the policy making process specified by them. 
The PHPDM models covering the aspects identified above 
will be automatically transformed into executable BDA 
processes and simulation processes whose execution would 
 
Figure 2 Envisaged physical architecture of EVOTION platform 
provide the basic evidence required for making a decision and 
exploring its consequences. 
V. RELATED WORK 
The development of the EVOTION platform is related to 
the several scientific and clinical research areas, the most 
prominent of which are (a) public health policy making and (b) 
big data analytics and decision making. In the following, we 
present an overview of research in (a) and (b). 
A. Public health policy making 
The World Health Organization (WHO) defines “health 
policy” as the “decisions, plans, and actions that are 
undertaken to achieve specific health care goals within a 
society” [16].	  Research on public health policy making has 
primarily focused on policy formation processes and 
guidelines. These may be related to four key stages in policy 
making, namely: (i) situational analysis (i.e., the assessment of 
the needs and gaps, the resources available, and eventually the 
strengths weaknesses, opportunities and threats (SWOT) 
arising in connection with a situation that needs to be 
addressed by health policy); (ii) development of action plan 
(i.e., setting the initial aim, objectives, activities and all 
priorities for implementing a health policy programme, and 
identifying the resources needed for this implementation); (iii) 
implementation and monitoring of programme; and (iv) 
programme evaluation (i.e., the assessment of the  effects and 
other outcomes of implemented health policy programme in 
long/medium term). 
The Canadian Foundation for Healthcare Improvement 
(CFHI) has developed a framework of 18 processes to support 
Evidence-Informed Health Policymaking [19]. These 
processes are aimed at ensuring that relevant research is 
identified, appraised and used to inform health policy 
decisions. CFHI guidelines cover all stages (i)-(iv) above, 
albeit (ii) more comprehensively WHO has developed a 
manual for planning and monitoring national health strategies, 
aimed at raising awareness about ear and hearing problems 
among individuals and communities. These have been tailored 
and targeted separately to the general public, policy-makers, 
programme managers and funding providers [18]. WHO's 
guidelines focus on use of SWOT in situational analysis, 
suggest aims for the development of action plans, identify sub-
phases in implementation and monitoring (i.e., pilot, 
expansion and evaluation). The applicability and 
transferability of evidence (ATE) tool [20][21] has been 
developed to help health planners make decisions about local 
health planning priorities. ATE focuses mainly on directing 
investigations of the literature as part of public health policy 
decision making to aid situational analysis. 
Although	 public health policy has a profound effect on 
health status, there is a considerable gap between what research 
shows as effective and the policies that are enacted and 
enforced. Research is most likely to influence policy 
development through an extended process of communication 
and interaction [23]. Systematic reviews of studies of decision-
making by health care policy-makers show that researchers 
could better inform health care management and policy-making 
by making several changes to how they produce and update 
systematic reviews and by adapting existing reviews that are 
relevant to local health care issues [27]. Also, according to a 
study on systematically reviewing qualitative and quantitative 
evidence to inform management and policy-making, policy-
makers and managers increasingly require access to high-
quality evidence syntheses that include research and non-
research evidence, and both qualitative and quantitative 
research findings [28]. 
The use of BDA has significant potential in reducing the 
costs of health care in several areas, including: high-cost 
patients, re-admissions, decompensation, adverse events, and 
treatment optimisation for diseases affecting multiple organ 
systems [24]. Further benefits from the use of BDA in 
healthcare include the potential for generating new knowledge, 
enabling personalised medicine, delivering information directly 
to patients and empowering them to play a more active role 
[25]. However, a prerequisite for successful learning from big 
health care data is to gain actionable insights into evidence 
generated by the data [26]. 
B. Big data analytics 
BDA can be separated into three parts (input, data 
analytics, and output) and seven operators (gathering, 
selection, pre-processing, transformation, data mining, 
evaluation, and interpretation). Nowadays, the data that need 
to be analysed are not just large, they are also composed of 
heterogeneous data types and real time streaming data. These 
characteristics make pre-processing an important task, and 
affect the applicability of statistical and data analysis 
approaches (as heterogeneous, incomplete and noisy and 
continually updated data affect the performance of the data 
analysis algorithms) [22]. 
Various solutions are available for BDA. These can be 
divided into (1) Processing/Compute (e.g., Hadoop [31], 
CUDA [32], and Twitter Storm [35]) (2) Storage (e.g., HDFS 
[33], HBase [34]), and (3) Analytics: MLPACK [29] or 
Mahout [30]. Although there are commercial products for data 
analysis, most of the studies on the traditional data analysis 
are focused on the design and development of efficient and/or 
effective “ways” to find the useful evidence in the data. 
Nevertheless, most of the current systems will not be able to 
handle the whole dataset all at once. Hence, designing a good 
data analytics framework becomes very important for the data 
analysis process. Data mining algorithms for data analysis also 
play a vital role in the BDA, in terms of the computation cost, 
memory requirement, and accuracy of the end results.  
Machine learning (ML) and data mining (DM) algorithms 
are essential for BDA. However, many of these algorithms are 
designed for sequential and/ centralised computing. ML/DM 
research for BDA has focused on making ML/DM algorithms 
run on parallel platforms, such as Radoop [36] and Mahout 
[30]; and redesigning ML/DM algorithms (e.g., population-
based algorithms) to make them suitable for parallel 
computing or to parallel computing environment (e.g., neural 
network algorithms for GPU and ant-based algorithm for 
grid). Despite these efforts, many research issues are still open 
including, for example, addressing communication cost for 
different computer nodes and the tackling the large 
computation cost of most ML/DM algorithms [22].  
VI. CONCLUDING REMARKS 
In this paper, we have introduced EVOTION, a new 
European research project, aims to develop an integrated 
platform supporting: (a) the analysis of related datasets to 
enable the identification of causal and other effects amongst 
them using various forms of big data analytics, (b) policy 
decision making focusing on the selection of effective 
interventions related to the holistic management of HL, based 
on the outcomes of (a) and the formulation of related public 
health policies, and (c) the specification and monitoring of 
such policies in a sustainable manner. In this position paper, 
we describe the EVOTION approach. 
The main overall contribution of EVOTION to existing 
research will be the development of a novel model driven 
platform for establishing public health policies for the 
management of HL, based on evidence arising from the 
analysis of static and dynamic health data. Our focus on HL 
management and the availability of related big data sets in this 
area, gives our research a clear driver and background 
framework for evaluation. To the best of our knowledge, the 
above contributions are clearly beyond the current state of the 
art and introduce a significant innovation potential to the 
management and treatment of HL, hearing deterioration and 
related cognitive decay. 
Beyond this, however, we believe that EVOTION has the 
potential to generate a generic platform for evidence based 
model driven public health policy making in other areas of 
healthcare, as well.  
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